title: Ticlopidine improves the enhanced erythrocyte aggregability in patients with cerebral infarction.
abstract: OBJECTIVE
  We examined the effect of ticlopidine hydrochloride on the enhanced erythrocyte aggregability in 14 patients with cerebral infarction during the chronic phase (over 1 month after onset).
  
  
  METHODS
  Ticlopidine (100 mg BID) was administered for 8 weeks. We measured the rate of erythrocyte aggregation (aggregability), using the whole-blood erythrocyte aggregometer that we developed, before and at 4 and 8 weeks after the initiation of ticlopidine administration. Concomitant measurements were made of such blood factors as the hematocrit, albumin-globulin ratio, and fibrinogen concentration. The erythrocyte aggregation rates before and at 4 and 8 weeks after were 0.147 +/- 0.017/s, 0.138 +/- 0.019/s, and 0.133 +/- 0.017/s, respectively. The erythrocyte aggregation rates at 4 and 8 weeks were significantly lower (P < .05 by Bonferroni's modified t test) than those before ticlopidine administration. At 4 and 8 weeks after the initiation of ticlopidine treatment, the hematocrit value and concentration of fibrinogen were also significantly (P < .05) reduced.
  
  
  CONCLUSIONS
  Our results suggest that ticlopidine can improve the enhanced erythrocyte aggregability in patients with cerebral infarction during the chronic phase.
authors.affiliation: Department of Neurology, School of Medicine, Keio University, Tokyo, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Tanahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Fukuuchi
authors.forename: M
authors.initials: M
authors.lastname: Tomita
authors.forename: S
authors.initials: S
authors.lastname: Matsuoka
authors.forename: H
authors.initials: H
authors.lastname: Takeda
mesh_terms: D000328:Adult; D000368:Aged; D002544:Cerebral Infarction / Q000097:blood / Q000188:drug therapy*; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D013988:Ticlopidine / Q000494:pharmacology*
chemical_list: D005340:Fibrinogen; D013988:Ticlopidine